<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781803</url>
  </required_header>
  <id_info>
    <org_study_id>HE21-00003</org_study_id>
    <nct_id>NCT04781803</nct_id>
  </id_info>
  <brief_title>Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome</brief_title>
  <official_title>Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome in Outpatient Haploidentical Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, randomized controlled, unblinded clinical trial. Will evaluate whether the&#xD;
      administration of oral cyclosporine started on day 0 of transplantation is effective in&#xD;
      reducing the incidence of cytokine release syndrome (CRS) in patients who receive an&#xD;
      outpatient haploidentical transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CRS is usually limited after the administration of post-transplant cyclosporine (PT-CsA)&#xD;
      administered on days +3 and +4, however, there is no standard prevention or treatment regimen&#xD;
      for CRS after haplo-TCPH and therapeutic behavior has usually been adopted.&#xD;
&#xD;
      Sample of 32 patients between the ages of 16 and 60 who receive their first haploidentical&#xD;
      transplant at our center. In the control group, CsA 6 mg/kg orally divided into two doses per&#xD;
      day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2&#xD;
      tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY)&#xD;
      at 50 mg/kg per day on days +3 and +4 and in the experimental group, CsA 6 mg/kg orally&#xD;
      divided into two doses per day starting in the morning on day 0 after transplantation,&#xD;
      mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50&#xD;
      mg/kg per day on day +3 and +4.&#xD;
&#xD;
      Will document the presence of CRS and its degree, as well as the need for hospitalization,&#xD;
      associated infectious processes, and a day to recover neutrophils and platelets.&#xD;
      Additionally, 4 blood samples will be taken from the patients to determine the level of&#xD;
      cytokines and C-reactive protein.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2021</start_date>
  <completion_date type="Anticipated">February 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine Release Syndrome</measure>
    <time_frame>day 0 to day 30</time_frame>
    <description>Presence of Fever, hypotension, hypoxemia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Cytokine Release Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 16-60 years of age who receive their first haploidentical transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients positive for the human immunodeficiency virus (HIV), Hepatitis B or C virus&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients with documented infection at the time of transplantation&#xD;
&#xD;
          -  Presence of previous autoimmune diseases&#xD;
&#xD;
          -  Inability to tolerate the oral route&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar González-Llano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario ¨Dr. José Eleuterio González</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perla R Colunga-Pedraza, MD</last_name>
    <phone>528183488510</phone>
    <phone_ext>378</phone_ext>
    <email>colunga.perla@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Colunga-Pedraza, MD</last_name>
    <phone>528183486136</phone>
    <phone_ext>435</phone_ext>
    <email>julia_ecp@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Dr. José E. González, Centro Universitario contra el Cáncer</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perla Colunga-Pedraza, MD</last_name>
      <phone>+5218110761973</phone>
      <email>colunga.perla@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>Chief of service</investigator_title>
  </responsible_party>
  <keyword>Cyclosporin</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Outpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

